Inorganic Growth Strategies is a Key Trend Gaining Market Momentum
1h Free Analyst Time
The celiac diseases drugs market is forecasted to grow by USD 1.10 billion during 2023-2028, accelerating at a CAGR of 21.21% during the forecast period. The report on the celiac diseases drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by higher consumption of gluten-containing food, increasing prevalence of celiac diseases, and government initiatives.
The celiac diseases drugs market is segmented as below:
By Therapy
- First line treatment
- Second-line treatment
By Route Of Administration
- Oral
- Parenteral
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the celiac diseases drugs market covers the following areas:
- Celiac diseases drugs market sizing
- Celiac diseases drugs market forecast
- Celiac diseases drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Therapy
7 Market Segmentation by Route of Administration
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global celiac diseases drugs market: 9 Meters Biopharma Inc, Adaptive Biotechnologies Corp., Almirall SA, Amgen Inc., AMYRA Biotech AG, Artielle Immunotherapeutics Inc, Avaxia Biologics Inc., BioLineRx Ltd., Bristol Myers Squibb Co., Calypso Biotech BV, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., ImmunogenX Inc., Johnson and Johnson Services Inc., Precigen Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Vactech Oy, and Zedira GmbH.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is inorganic growth strategies."
According to the report, one of the major drivers for this market is the higher consumption of gluten-containing food.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 9 Meters Biopharma Inc
- Adaptive Biotechnologies Corp.
- Almirall SA
- Amgen Inc.
- AMYRA Biotech AG
- Artielle Immunotherapeutics Inc
- Avaxia Biologics Inc.
- BioLineRx Ltd.
- Bristol Myers Squibb Co.
- Calypso Biotech BV
- GlaxoSmithKline Plc
- Glenmark Pharmaceuticals Ltd.
- ImmunogenX Inc.
- Johnson and Johnson Services Inc.
- Precigen Inc.
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Vactech Oy
- Zedira GmbH
